Share in X

Etanercept Biosimilar Market Size, Share, Forecast Report 2026 to 2035

Report ID: 1068 Pages: 180 Updated: 14 April 2026 Format: PDF / PPT / Excel / Power BI

What is Etanercept Biosimilar Market Size?

Global Etanercept Biosimilar Market Size is valued at USD XX Mn in 2025 and is predicted to reach USD XX Mn by the year 2035 at an 18.00% CAGR during the forecast period for 2026 to 2035.

Etanercept Biosimilar Market Size, Share & Trends Analysis Report By Applications (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, And Ankylosing Spondylitis), Distribution Channel, Region And Segment Forecasts, 2026 to 2035

Etanercept Biosimilar Market

Etanercept Biosimilar Market Key Takeaways:

  • Etanercept Biosimilar Market Size is valued at USD XX Mn in 2025 and is predicted to reach USD XX Mn by the year 2035
  • Etanercept Biosimilar Market is predicted to grow at an 18.0% CAGR during the forecast period for 2026 to 2035.
  • Etanercept Biosimilar Market is segmented into Brand, Applications, Distribution Channel and Other.
  • North America region is leading the Etanercept Biosimilar Market

Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor-alpha (TNF-α) inhibitor approved for the treatment of rheumatoid arthritis. It is also approved for the treatment of juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Etanercept competitively inhibits the binding of TNF to cell surface receptors and thus makes TNF biologically inactive. By doing so, the drug inhibits the pro-inflammatory effects of TNF and thereby leads in a reduction of joint inflammation. Etanercept was developed and marketed by Amgen and Pfizer. The drug was approved by the U.S. Food Drug and Administration in November 1998. It was approved in Europe by European Medicines Agency in February 2000. It is marketed under the trade name of ‘Enbrel’.

Expiration of patent and near-term expiration of patent has led to the entry of biosimilar into the market. The patent of Enbrel is expired in Europe in August 2015 and will expire in the U.S. in November 2028. Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. Reducing treatment cost is the principal attraction factor for the growth of etanercept biosimilars market. Thus many of biosimilar of etanercept are currently approved and some are in development phase which are expected to come into the market during forecast period. Introduction to biosimilars, increase in incidence and prevalence rate of various articular diseases, and rising demand for cost effective alternatives are the factors boosted the growth of etanercept biosimilar market. However, stringent regulatory process for the approval of etanercept biosimilar and complicated manufacturing process are the major restrain factors for the growth of the etanercept biosimilar market.

Competitive Landscape

Some of The Key Players in The Etanercept Biosimilar Market:

  • Samsung Bioepis
  • Sandoz (Novartis generics division)
  • Mylan
  • Lupin
  • YL Biologics
  • Cipla
  • Sunshine Guojian Pharmaceutical
  • LG Chem
  • Hanwha Chemical
  • Merck
  • Biogen
  • Shanghai CP Guojian Pharmaceutical
  • AYUMI Pharmaceutica
  • Other prominent players

Market Segmentation

The global etanercept biosimilar market is segmented on the basis of application, distribution channel and geography. Based on the application global etanercept biosimilar market is segmented into rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Rheumatoid arthritis segment is expected to grow at higher pace during the forecast period owing to increasing incidence and prevalence rate. Based on distribution channel the global etanercept biosimilar market is segmented as hospital pharmacy, online pharmacy and others. Online pharmacy segment is expected to grow during forecast period due to increase in number of internet users and ease of use.

Geographically, the global etanercept biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by Asia Pacific is major contributor for the global etanercept biosimilar market. This is because early patent expiry, entry of etanercept biosimilars, strong clinical pipeline, increasing research and drug development activities, presence of major players, and developing healthcare infrastructure propels the growth of the market in the region. Asia Pacific is promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Huge population base in countries such as China and India offers tremendous market opportunities for the etanercept biosimilar market. North America is third major contributor for the market in forecast period and is expected to grow at rapid pace, due to presence of strong clinical pipeline.

Etanercept Biosimilar Market

Etanercept Biosimilar Market Report Scope :

Report Attribute Specifications
Market Size Value In 2025 USD XX Mn 
Revenue Forecast In 2035 USD XX Mn 
Growth Rate CAGR CAGR of 18.0% from 2026 to 2035
Quantitative Units Representation of revenue in US$ Million and CAGR from 2026 to 2035
Historic Year 2022 to 2025
Forecast Year 2026-2035
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered Brand, Applications, Distribution Channel
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia
Competitive Landscape Avesthagen, Cipla, LG Life Sciences, Protalix Biotherapeutics, BioXpress Therapeutics, Sandoz, Celltrion, Teva Pharmaceutical Industries, Pfizer, Samsung Bioepis, mAbxience, and Others
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing and Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation of Etanercept Biosimilar Market :

Etanercept Biosimilar Market, By Brand-

  • Benepali
  • Brenzys
  • Erelzi
  • Eticovo
  • Nepexto
  • Rymti
  • Others (Products approved in developing countries & pipeline products)

 Etanercept Biosimilar Market

Etanercept Biosimilar Market, By Application-

  • Rheumatoid arthritis
  • Juvenile rheumatoid arthritis
  • Psoriatic arthritis
  • Plaque psoriasis
  • Ankylosing spondylitis

Etanercept Biosimilar Market, By Distribution Channel-

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other 

Etanercept Biosimilar Market, By Region-

  • North America-
    • The US
    • Canada
  • Europe-
    • Germany
    • The UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific-
    • China
    • Japan
    • India
    • South Korea
    • South East Asia
    • Rest of Asia Pacific
  • Latin America-
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  •  Middle East and Africa-
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Request Customization

Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.

Customize This Report →

Enquire Before Buying

Speak with our analyst team about scope, methodology, pricing, or deliverable formats.

Enquire Now →

Frequently Asked Questions

How big is the Etanercept Biosimilar Market Size?

Etanercept Biosimilar Market Size is valued at USD XX Mn in 2025 and is predicted to reach USD XX Mn by the year 2035

What is the Etanercept Biosimilar Market Growth?

Etanercept Biosimilar Market is expected to grow at an 18.0% CAGR during the forecast period for 2026 to 2035

Who are the key players of the Etanercept Biosimilar Market?

Avesthagen, Cipla, LG Life Sciences, Protalix Biotherapeutics, BioXpress Therapeutics, Sandoz, Celltrion, Teva Pharmaceutical Industries, Pfizer, Samsung Bioepis, mAbxience, and Others

What are the key segments of the Etanercept Biosimilar Market?

Etanercept Biosimilar Market is segmented into Brand, Applications, Distribution Channel and Other.

Which region is leading the Etanercept Biosimilar Market?

Europe region is leading the Etanercept Biosimilar Market.

FREE SAMPLE REPORT

Get Your Market Report Sample

See the data, methodology, and competitive landscape preview & delivered to your inbox shortly.

Check your inbox shortly after submitting. If you don't see our email, please check your External, Spam, Junk, or Promotions folder.

Trusted by Sartorius, L'Oreal, Fujifilm & 370+ organizations

KOL-Validated Research Analyst-Built Models Direct Analyst Access
Send me Sample Report Request for Customization